Compare Lennar Corporation (LEN) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lennar Corporation vs Moderna, Inc. — how do they compare? Lennar Corporation trades at $76.73 (market cap $18.44B), while Moderna, Inc. trades at $224.91 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 4.3× Lennar Corporation's market cap, and Lennar Corporation pays a 2.58% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lennar Corporation for 67 Days and Moderna, Inc. for 59 Days on average.
| LEN | MRNA | |
|---|---|---|
Market Cap | $18.44B | $78.65B |
Volume | 6,012,214 | 37,373,437 |
Sector | Consumer Cyclical | Health |
52-Week High | $133.13 | $203.46 |
52-Week Low | $74.44 | $22.36 |
Typical Hold Time | 67 Days | 59 Days |
Enterprise Value | $22.86B | $74.80B |
Dividend Yield | 2.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LEN trades at $76.69, up 0.74% on the day, with a bearish technical signal from moving averages and oscillators. Recent earnings show three consecutive quarterly misses against expectations, with Q3 2026 results pending. Revenue declined to $34.19B in 2025 from $35.4B in 2024, while net income fell to $2.08B. Valuation metrics appear attractive with P/E of 14.7 and P/B of 0.86. Berkshire Hathaway has been accumulating shares, building an 11.2% stake as of October 2026.
The stock presents a value opportunity with below-book valuation and strong institutional interest, but faces headwinds from declining profitability and housing market challenges. Near-term risks include potential earnings volatility and high mortgage rates, while long-term prospects benefit from Berkshire's strategic positioning and the company's asset-light transition.
Moderna (MRNA) trades at $225.00, up 14.52% in 24 hours, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $194. Fundamentally, while revenue has declined from pandemic peaks to $1.92B in 2025, the company continues to beat EPS expectations and maintains a robust pipeline in oncology and respiratory vaccines. Recent inclusion in the Nasdaq-100 index has generated positive momentum, though valuation metrics remain elevated with a P/S ratio of 35.08.
Outlook remains bifurcated - significant growth potential exists in the cancer vaccine pipeline and respiratory vaccine expansion, but current valuations appear stretched relative to financial performance. Key risks include execution challenges in new therapeutic areas, competitive pressure from Pfizer/BioNTech, and dependence on pipeline success beyond COVID-19 vaccines. Analyst consensus shows cautious optimism with a $115.70 price target despite recent downgrades.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
